EQ
Equillium, Inc.
Biotechnology · Healthcare · United States
1.37
close · 2026-10-30
value
52
cheaper than peers52
quality
65
stronger fundamentals65
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.55× | 66 |
| earnings yield, 1 year ago | -16.8% | 62 |
| cash flow yield, 3 years ago | -8.4% | 58 |
| earnings yield, 2 years ago | -27.7% | 57 |
| earnings yield, latest year | -28.5% | 50 |
| cash flow yield, 1 year ago | -17.8% | 48 |
| cash flow yield, latest year | -21.2% | 46 |
| cash flow yield, 2 years ago | -20.3% | 45 |
| earnings yield, 3 years ago | -135.0% | 30 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.0% | 71 |
| return on equity | -59.0% | 53 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $107M |
| free cash flow | -$15.1M |
| employees | 14 |
| first trade | 2018-10-12 |
| next earnings | not reported |
| fundamentals updated | 2026-08-18 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.39 | -0.23 | -0.38 | -1.85 | not reported |
| free cash flow | -$22.8M | -$19.1M | -$21.8M | -$9.0M | not reported |
| net income | -$22.4M | -$8.1M | -$13.3M | -$62.4M | not reported |
| revenue | $0 | $41.1M | $36.1M | $15.8M | not reported |
| unusual items | not reported | not reported | $0 | -$23.0M | $0 |